Optimize Current Medications and Consider SSRI Addition
For this 83-year-old male with persistent anxiety despite buspirone and quetiapine, the most appropriate next step is to increase buspirone to therapeutic doses (up to 20-30 mg twice daily) and strongly consider adding an SSRI, specifically sertraline or escitalopram, as first-line pharmacotherapy for anxiety in older adults. 1
Current Medication Assessment
The patient's current regimen is suboptimal:
Buspirone 5 mg BID (10 mg/day total) is below the therapeutic range. Studies in elderly patients demonstrate efficacy at mean doses of 18 mg/day, with a typical range of 15-30 mg/day 2, 3. Buspirone requires 2-4 weeks to become effective and should be titrated gradually 4.
Quetiapine 25 mg nightly is a very low dose. While quetiapine has demonstrated efficacy for anxiety in mood disorders 5, it carries significant risks in elderly patients including falls, orthostatic hypotension, anticholinergic effects, metabolic disturbances, and cognitive impairment 6. The 2025 geriatric emergency guidelines note that oral quetiapine has a favorable safety profile for agitation 7, but this patient's persistent anxiety suggests the current dose is inadequate for therapeutic effect while still exposing him to adverse risks.
Recommended Treatment Algorithm
Step 1: Optimize Buspirone (Immediate)
- Increase buspirone to 10 mg BID (20 mg/day), then consider further titration to 15 mg BID (30 mg/day) if tolerated
- Allow 2-4 weeks at each dose to assess response 4
- Buspirone is well-tolerated in elderly patients with minimal side effects and no sedation, cognitive impairment, or abuse potential 2, 3, 8
Step 2: Add SSRI as First-Line Agent (Strongly Recommended)
Preferred SSRIs for elderly patients:
- Sertraline (start 25 mg daily, target 50-100 mg daily) OR
- Escitalopram (start 5 mg daily, target 10 mg daily)
These agents are specifically recommended for older adults with anxiety due to favorable side effect profiles and lower drug interaction potential 1, 9. Escitalopram/citalopram have the least effect on CYP450 enzymes, reducing drug-drug interaction risk 10.
Titration approach:
- Start at subtherapeutic "test" dose to minimize initial anxiety exacerbation 10
- Increase in smallest increments every 1-2 weeks for shorter half-life SSRIs (sertraline) 10
- Allow 4-8 weeks for full therapeutic trial 9
- SSRIs are effective for both generalized anxiety and panic attacks 11, 12
Step 3: Address Fall Risk Concerns
The patient's worry about falling is clinically significant:
Quetiapine increases fall risk through somnolence, orthostatic hypotension, and motor impairment 6. The FDA label explicitly warns "somnolence may lead to falls" 6.
Consider tapering quetiapine once SSRI reaches therapeutic effect, as the risk-benefit ratio is unfavorable at this low, subtherapeutic dose
Avoid benzodiazepines entirely - they increase fall risk, cause paradoxical agitation in 10% of elderly patients, and lead to cognitive impairment 4. The 2025 guidelines show midazolam posed elevated risk without efficacy gains, and lorazepam showed dose-dependent adverse events 7.
Critical Cautions
What NOT to do:
- Do not add benzodiazepines - regular use causes tolerance, addiction, depression, cognitive impairment, and increased fall risk 4, 13
- Avoid paroxetine and fluoxetine in elderly due to higher adverse effect rates 9
- Do not use quetiapine as monotherapy for primary anxiety disorder at low doses - insufficient evidence and excessive risk 7
Drug interactions to monitor:
- Quetiapine has anticholinergic effects; avoid combining with other anticholinergic medications 6
- Check for QT-prolonging medications if using citalopram (max 20 mg/day in elderly) 10
Alternative if SSRI Contraindicated
If SSRIs are not tolerated or contraindicated, the algorithm suggests 1:
- Third-line options: Pregabalin/gabapentin, SNRIs (venlafaxine, duloxetine)
- Fourth-line: Consider quetiapine at therapeutic doses (150-300 mg/day), but only after careful risk-benefit analysis given age-related adverse effects
Monitoring Plan
- Weekly follow-up during first month to assess adherence, side effects, and address medication concerns 11
- Assess for orthostatic hypotension, falls, cognitive changes
- Monitor for initial SSRI-induced anxiety (typically resolves within days) 10
- Evaluate response at 4-8 weeks; if inadequate, switch to alternative SSRI or add SNRI 1
The evidence strongly supports that this patient is undertreated with subtherapeutic doses of both current medications, while being exposed to unnecessary fall risk from low-dose quetiapine. The priority is optimizing buspirone and adding an SSRI, which have the strongest evidence base for anxiety in elderly patients with favorable safety profiles 1, 11, 12.